What to Expect in October's Multidrug-Resistant Infections Section of Contagion®
Samuel L. Aitken, PharmD, MPH, discusses the article he wrote with Dr. Sarah L. Spitznogle for the October issue of Contagion® evaluating the role of new β-lactam agents for uncommon pathogens.
Segment Description: Samuel L. Aitken, PharmD, MPH, clinical pharmacy specialist in infectious disease at The University of Texas MD Anderson Cancer Center, discusses the article he wrote with Dr. Sarah L. Spitznogle for the October issue of Contagion® evaluating the role of new β-lactam agents for uncommon pathogens.
Interview transcript: (modified slightly for readability)
Dr. Aitken: In the October issue of Contagion®, our PGY2 ID pharmacy resident Sarah Spitznogle and I take a look at the role of new beta-lactam/beta-lactamase inhibitors and the new beta-lactam agent cefiderocol against novel or difficult-to-treat non-lactose fermenters. So those are Stenotrophomonas, Achromobacter, and Burkholderia and, in that piece, we sort of take a mechanistic dive into why these things are resistant to so many different antimicrobials and, using that, can sort of form a basis for what drugs may or may not be active, understanding what drives beta-lactam resistance.
